Drug Trial Radar · NCT01414075
Study of Roxadustat (FG-4592) to Correct Anemia in Newly Initiated Dialysis Participants Not on Erythropoiesis-Stimulating Agent Treatment
Last checked: Nov 20, 2026Latest source record: Oct 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
60
Actual
Start
Jul 21, 2011
Primary completion
Jan 10, 2013
Study completion Jan 10, 2013
Sponsor
- Lead sponsor
- Kyntra BioIndustry
- Sponsor type
- Industry
- Collaborators
- Astellas Pharma Inc
- First posted
- Aug 11, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate efficacy and safety of roxadustat in the correction of anemia in participants with end-stage renal disease who recently started dialysis.
Conditions
- Dialysis
- Anemia
Interventions
RoxadustatDrug
Tiered, weight-based dosing per schedule specified in the arm.
Oral IronDrug
Administered per oral dose and schedule specified in the arm.
IV IronDrug
Administered per IV dose and schedule specified in the arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Change From Baseline in Hb During Weeks 3-13Time frame: Baseline, Weeks 3-13
Locations
7 sites in 4 countries. Site status is shown where the registry gives one.
Site not named
Northridge, California
Site not named
Yuba City, California
Site not named
Detroit, Michigan
Site not named
Hong Kong, Hong Kong
Site not named
Moscow, Russia
Site not named
Saint Petersburg, Russia
Site not named
Singapore, Singapore
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.